DERMATOSCOPY AS A METHOD OF EVALUATING THE EFFICIENCY OF 5% CREAM IMYKVIMOD IN PATIENTS WITH BASAL CELL CARCINOMA OF SKIN

Cover Page


Cite item

Full Text

Abstract

The aim. investigation of the possibilities of dermatoscopy as a method for evaluating the effectiveness of therapy with topical imiquimod in patients with superficial basal cell carcinoma (CCB). Materials and methods. the study included 24 patients with a superficial form of CCB, who for various reasons did not undergo excisional surgical intervention and who agreed to alternative drug therapy (officinal original topical imiquimod). Patients were divided into two groups, in which the efficacy of therapy was assessed either by clinical or by dermatoscopic signs. General results. the study demonstrated the importance of dermatoscopy as a method for assessing the effectiveness of therapy with topical imiquimod; Greater prognostic significance of dermatoscopy in comparison with a simple clinical examination of mass when assessing the moment of interruption of drug therapy with imiquimod.

About the authors

M. V. Zhuchkov

Ryazan Regional Clinical Skin and Venereal Diseases Dispensary; Ryazan State Medical University

Author for correspondence.
Email: misha.juchkov@gmail.com
Sport str., 9, Ryazan, 390046, Russia; Vysokovoltnaya str., 9, Ryazan, 390026, Russia Russian Federation

D. B. Sonin

Ryazan Regional Clinical Skin and Venereal Diseases Dispensary

Email: fake@neicon.ru
Sport str., 9, Ryazan, 390046, Russia Russian Federation

M. A.  Tarasova

Ryazan Regional Clinical Skin and Venereal Diseases Dispensary; Ryazan State Medical University

Email: fake@neicon.ru
Sport str., 9, Ryazan, 390046, Russia; Vysokovoltnaya str., 9, Ryazan, 390026, Russia Russian Federation

S. A. Kosorukova

Ryazan State Medical University

Email: fake@neicon.ru
Vysokovoltnaya str., 9, Ryazan, 390026, Russia Russian Federation

References

  1. Lubeek S.F. et al. The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older: A Systematic Review. JAMA Dermatol. 2017 Jan 1; 153 (1): 71—78.
  2. Hogan D.J., To T., Gran L., Wong D., Lane P. R. Risk factors for basal cell carcinoma. Int J Dermatol 1989 Nov; 28 (9): 591—594.
  3. Silapunt S., Chen L., Migden M. R. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol 2016 Sep; 8 (5): 375—82.
  4. Ceilley R. I., Del Rosso J.Q. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006 May; 45 (5): 489—98.
  5. Gniadecki R. et al. Favourable results of Mohs micrographic surgery for basal cell carcinoma. Dan Med J 2015 Dec; 62 (12): A5171.
  6. Zou Y. et al. Photodynamic therapy versus surgical excision to basal cell carcinoma: metaanalysis. J Cosmet Dermatol 2016 Dec; 15 (4): 374—382.
  7. Piccinno R. et al. Dermatologic radiotherapy in the treatment of extensive basal cell carcinomas: a retrospective study. J Dermatolog Treat 2017 Jan 29: 1—5.
  8. Graells J., Ojeda R.M., García-Cruz A. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma. Actas Dermosifiliogr. 2014 Jan-Feb; 105 (1): 53—9.
  9. Soong R.S. et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clin Cancer Res 2014 Nov 1; 20 (21): 5456—5467.
  10. Telò I. et al. Mechanisms of imiquimod skin penetration. Int J Pharm 2016 Sep 10; 511 (1): 516—523.
  11. Kaçar S.D., Özuguz P., Erkan F., Karaca S¸. Treatment of various types of basal cell carcinoma with topical 5% imiquimod in the elderly who refused surgical intervention: a case series. J Dermatolog Treat 2015 Apr; 26 (2): 165—167.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Zhuchkov M.V., Sonin D.B., Tarasova M.A., Kosorukova S.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies